UNSPSC 51431801: Irbesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C25H28N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0E2756Z7N, chemically known as 1,3-diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)- but generally known as irbesartan, which bears US NIH Compound Identifier 3749. European Medicines Agency schedules Irbesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08293MIG.

UNSPSC 51431801 Irbesartan is a Commodity code identifying a specific pharmaceutical product—an antihypertensive agent—that state and local governments procure primarily through emergency medical services, pharmacy benefit programs, and health benefit purchasing cooperatives. Recent solicitations show state and local buyers acquiring irbesartan and similar medications in two distinct procurement contexts: direct purchase of finished medications for immediate use by emergency responders, and participation in cooperative purchasing agreements that establish pricing and supply arrangements across multiple jurisdictions. The City of Tampa's Purchasing Department, Minnesota's multistate cooperative (MMCAP), and the Texas Health and Human Services Commission represent the issuing-body mix—municipal fire and rescue services, state pharmacy benefit administrators, and cooperative purchasing vehicles serving multiple state and local participants. Scope of work includes supply of medications meeting specific National Drug Codes, expiration-date requirements (typically nine months minimum from acceptance), OSHA Safety Data Sheet compliance, FDA manufacturing standards, and wholesaler distribution arrangements.

Geographic activity concentrates in Texas, Minnesota, and Florida based on recent postings, with MMCAP's cooperative structure extending potential reach across Oregon and other member states. The City of Tampa issued IFB No. 26P00188 on April 24, 2026, requesting 370 units of Labetalol HCl, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000—the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. Minnesota's MMCAP posted RFP S1070000015802 on January 20, 2026, establishing multi-year contracts for generic pharmaceuticals and OTC products through authorized wholesalers with proposals due March 26, 2026, and award effectiveness July 1, 2026; evaluation weighted 75 percent on price competitiveness and 25 percent on administrative, data, and compliance factors. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, signaling early-stage state interest in alternative pharmacy supply models outside traditional PBM and GPO channels.